 |
KCC: Results of Search for JOG protocols
Open Jefferson Oncology Group (JOG) Clinical Trials
|
(click on the "Protocol #
" below for additional information on that trial)
|
08C.532 (JOG 049): Myeloma
Purpose: To define the objective response rate associated with the administration of vorinostat in combination with bortezomib to patients with relapsed and refractory multiple myeloma after at least 2 prior treatment regimens, who meet both of the following conditions:
1.) refractory to bortezomib, defined as no response or disease progression in 60 days
2.) relapsed, refractory, intolerant, and/or ineligible to other therapies, including an IMiD according to the investigator
Title: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination with Bortezomib in Patients with Relapsed or Refractory Multiple Myeloma
|
Web page revised:
February 1, 2008
URL: http://www.kimmelcancercenter.org/CancerClinicalTrials/getjogprotocols.php
|
